Company Overview

Hypera S.A. is a Brazil-based pharmaceutical and consumer health company engaged in the development, manufacturing, marketing, and distribution of prescription medicines, over-the-counter (OTC) products, generics, branded generics, vitamins, dermatological products, and health-related consumer goods. The company operates primarily in the pharmaceutical and consumer healthcare industries and is one of the largest pharmaceutical companies in Brazil by market presence and brand portfolio. Its revenue is primarily driven by branded prescription drugs, OTC medicines, and established consumer health brands sold through pharmacies, distributors, hospitals, and retail chains.

The company traces its origins to Prática Laboratórios and later evolved through a series of mergers, restructurings, and acquisitions before adopting the Hypera identity. Hypera expanded significantly through acquisitions of established pharmaceutical portfolios and consumer health assets in Brazil, including products acquired from multinational pharmaceutical companies divesting non-core brands. Its strategic positioning is supported by strong brand recognition in the Brazilian healthcare market, extensive domestic distribution capabilities, and a diversified portfolio across therapeutic categories including pain relief, digestive health, dermatology, respiratory care, and vitamins.

Business Operations

Hypera organizes its operations around pharmaceutical and consumer healthcare activities, with core business units focused on branded prescription medicines, OTC products, generics, and health-related consumer brands. Key brands and operations are managed through integrated commercial, manufacturing, and logistics systems within Brazil. The company generates revenue primarily through sales to pharmacies, wholesalers, distributors, hospitals, and large retail pharmacy chains. Hypera maintains manufacturing facilities, research and development operations, and distribution infrastructure designed to support nationwide product availability.

The company controls a broad portfolio of pharmaceutical trademarks and consumer health brands, including products acquired from companies such as Takeda Consumer Health Latin America, Buscopan, and other established portfolios integrated into its operations. Hypera has historically pursued strategic licensing agreements, product acquisitions, and partnerships aimed at strengthening its position in high-volume therapeutic categories. Although its operational base is concentrated in Brazil, the company also maintains selected international commercial activities and export relationships in Latin American markets.

Strategic Position & Investments

Hypera’s strategic direction has centered on expanding higher-margin branded products, strengthening its OTC leadership position, and increasing operational efficiency through portfolio optimization and scale. The company has invested heavily in marketing, manufacturing capacity, logistics infrastructure, and product development to reinforce its competitive standing in Brazil’s pharmaceutical sector. Growth initiatives have included acquisitions of mature pharmaceutical brands from multinational firms seeking to streamline their portfolios in Latin America.

Among the company’s notable strategic transactions was the acquisition of portions of Takeda’s consumer healthcare business in Latin America, which expanded Hypera’s portfolio of established brands and increased its scale in the OTC segment. Hypera has also invested in digital commercial capabilities, supply chain modernization, and product innovation in areas such as dermatology, vitamins, and chronic care medications. Public disclosures and market reporting indicate that the company remains focused on cash generation, portfolio expansion, and long-term leadership in Brazil’s branded pharmaceutical market.

Geographic Footprint

Hypera is headquartered in São Paulo, Brazil, and its operations are primarily concentrated in the Brazilian market, which represents the substantial majority of its revenue and commercial activity. The company maintains nationwide manufacturing, logistics, sales, and distribution operations serving pharmacies, hospitals, and healthcare retailers across Brazil’s major regions. Its domestic scale and broad retail penetration are considered central competitive advantages within the country’s pharmaceutical industry.

Beyond Brazil, Hypera maintains limited international exposure through exports and regional commercial relationships in parts of Latin America. While the company does not maintain the same global operational footprint as major multinational pharmaceutical firms, its influence within Brazil positions it as one of the country’s most significant domestically headquartered pharmaceutical companies. Public filings and investor materials consistently identify Brazil as the company’s core strategic and operational market.

Leadership & Governance

Hypera operates under a corporate governance structure aligned with Brazilian public market standards and is listed on B3 – Brasil Bolsa Balcão. The company’s leadership strategy has emphasized disciplined capital allocation, brand portfolio expansion, operational efficiency, and sustained investment in commercial execution. Governance disclosures in annual filings and investor materials indicate a focus on long-term shareholder returns, market leadership in branded pharmaceuticals, and continued strengthening of the company’s consumer health platform.

Key executives include:

• Breno Oliveira – Chief Executive Officer
• Fabio Herkenhoff – Chief Financial Officer and Investor Relations Officer
• Nelson Mussolini – Vice President of Operations
• Marcelo Khouri – Vice President of Commercial Operations
• Andrea De Luca – Vice President of Marketing and Consumer Health

Executive roles and reporting structures may change over time based on corporate filings and public disclosures. Data regarding certain leadership appointments may vary slightly across public sources due to timing differences in reporting updates.